Target type: biologicalprocess
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ether stimulus. [GOC:go_curators]
Response to ether is a complex biological process that involves a cascade of events triggered by the interaction of ether with specific receptors and signaling pathways within the cell. Ether, a volatile and highly flammable liquid, is an anesthetic agent that acts primarily on the central nervous system. Upon exposure to ether, it rapidly enters the bloodstream and crosses the blood-brain barrier, reaching the brain and other organs.
In the brain, ether interacts with various receptors, including the nicotinic acetylcholine receptor (nAChR), gamma-aminobutyric acid (GABA) receptors, and N-methyl-D-aspartate (NMDA) receptors. These interactions lead to alterations in neuronal excitability and synaptic transmission.
The activation of nAChRs by ether can result in increased release of neurotransmitters, such as acetylcholine and dopamine, which contribute to the anesthetic effects of ether. Ether also enhances the activity of GABA receptors, which inhibit neuronal activity and induce sedation. Conversely, ether can block the function of NMDA receptors, which play a role in learning and memory.
The interaction of ether with these receptors triggers a complex signaling cascade involving various intracellular pathways. These pathways involve activation of second messengers, such as cyclic adenosine monophosphate (cAMP) and inositol triphosphate (IP3), which modulate neuronal activity and contribute to the anesthetic effects of ether.
In addition to its effects on the central nervous system, ether can also affect other organs, including the cardiovascular system, respiratory system, and liver. The effects on these organs may vary depending on the concentration and duration of exposure to ether.
The response to ether is influenced by several factors, including the individual's genetic makeup, age, and overall health. Some individuals may exhibit greater sensitivity to ether, while others may be more resistant.
Overall, the response to ether is a complex process that involves multiple cellular and molecular mechanisms. The interaction of ether with specific receptors and signaling pathways within the cell leads to alterations in neuronal activity and synaptic transmission, resulting in anesthetic effects and other physiological changes. The specific effects of ether can vary depending on factors such as concentration, duration of exposure, and individual susceptibility.'
"
Protein | Definition | Taxonomy |
---|---|---|
E3 ubiquitin-protein ligase Mdm2 | An E3 ubiquitin-protein ligase Mdm2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q00987] | Homo sapiens (human) |
Tyrosine 3-monooxygenase | A tyrosine 3-monooxygenase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P07101] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
catechol | catechols | allelochemical; genotoxin; plant metabolite | |
gossypol | Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer. | ||
quinone | 1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene. benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups. quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included). | 1,4-benzoquinones | cofactor; human xenobiotic metabolite; mouse metabolite |
vorinostat | vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. | dicarboxylic acid diamide; hydroxamic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor |
apomorphine | Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. | aporphine alkaloid | alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug |
cytarabine | beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside | antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent | |
n-n-propylnorapomorphine | aporphine alkaloid | ||
nutlin 3 | stilbenoid | ||
monoiodotyrosine | 3-iodo-L-tyrosine : The monoiodotyrosine that is L-tyrosine carrying an iodo-substituent at position C-3 of the benzyl group. iodotyrosine : A tyrosine derivative which has at least one iodo-substituent on the benzyl moiety. monoiodotyrosine : An iodotyrosine carrying a single iodo substituent. Monoiodotyrosine: A product from the iodination of tyrosine. In the biosynthesis of thyroid hormones (THYROXINE and TRIIODOTHYRONINE), tyrosine is first iodized to monoiodotyrosine. | amino acid zwitterion; L-tyrosine derivative; monoiodotyrosine; non-proteinogenic L-alpha-amino acid | EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor; human metabolite; mouse metabolite |
nutlin 2 | |||
nutlin 1 | nutlin 1: an MDM2 antagonist; structure in first source | ||
11-hydroxy-n-(n-propyl)noraporphine hydrochloride, (r)-isomer | |||
nutlin-3a | nutlin 3: an MDM2 antagonist; structure in first source | stilbenoid | |
MI-63 | MI-63 : An azaspiro compound resulting from the formal fusion of position 3 of 6-chloro-oxindole with position 3 of (2R,3SS5S)-3-(3-chloro-2-fluorophenyl)-5-(2,2-dimethylpropyl)-N-[2-(morpholin-4-yl)ethyl]pyrrolidine-2-carboxamide. It is a potent inhibitor of the MDM2-p53 interaction. | azaspiro compound; monochlorobenzenes; monofluorobenzenes; morpholines; oxindoles; pyrrolidines; secondary carboxamide | apoptosis inducer |
nutlin-3b | Nutlin; piperazinone | anticoronaviral agent | |
pb 12 | |||
spautin-1 | |||
nvp-cgm097 | NVP-CGM097: an MDM2 and HDM2 inhibitor; structure in first source | ||
rg7388 | RG7388: structure in first source | ||
sar405838 | SAR405838: an inhibitor of the interaction of MDM2 and p53; has antineoplastic activity; structure in first source | ||
rg7112 | |||
amg 232 |